3Vardiman JW, Harris NL, Brunning RD. The World Health Organization ( WHO ) classification of the myeloid neoplasms [ J ]. Blood, 2002, 100(7) : 2292 -2302.
4Baxter E J, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[ J]. Lancet, 2005, 365(9464): 1054-1061.
5Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. N Engl J Med, 2005, 352(17) : 1779 - 1790.
6Ingley E , Klinken SP. Cross-regulation of JAK and Src kinases[ J]. Growth Factors, 2006, 24 ( 1 ) : 89 - 95.
7Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a routine bone marrow transplant model [ J ]. Blood, 2006, 107 (11) : 4274 -4281.
8Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology[ J]. J Mol Diagn, 2006, 8(4) : 397 -411.
9Izmailov A, Goloubentzev D, Jin C, et al. A general approach to the analysis of errors and failure modes in the base-calling function in automated fluorescent DNA sequencing [ J ]. Electrophoresis, 2002, 23 (16) : 2720 -2728.
10Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [ J ]. N Engl J Med, 2007, 356(5) : 459 -468.
